Clinical trials: Resectable Head and Neck Squamous Cell Carcinoma
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
- Trial name
- NCT04630353
- Testing
- HB-201 IV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Head and Neck Squamous Cell Carcinoma
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection.
- Trial name
- NCT06444009
- Testing
- Ivonescimab combined with TP, Cadonilimab combined with TP, Penpulimab combined with TP
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lei Liu
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death protein 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant…
- Trial name
- NCT06109207
- Testing
- Camrelizumab, Dalpiciclib 100mg, Dalpiciclib 150mg
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Tislelizumab), targeted therapy (Cetuximab), with chemotherapy (Cisplatin and Nab-paclitaxel) as a possible…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma, Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OSCC (NCT06728618)
- Testing
- Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Oral Squamous Cell Carcinoma (OSCC)
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
This study is a multicenter, prospective, single-arm Phase II clinical trial evaluating the efficacy and safety of neoadjuvant therapy with TROP-2 ADC in combination with toripalimab for resectable locally advanced oral squamous…
- Trial name
- NCT07778368
- Testing
- Sacituzumab Govitecan OR Sacituzumab Tirumotecan in Combination with Toripalimab, Radical Surgery for OSCC, Radiation Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai East Hospital
Esophageal Squamous Cell Carcinoma
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Abstract Objective: This study aims to investigate the potential clinical impact of neoadjuvant immunotherapy in resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06388135
- Testing
- Serplulimab Combined With Nab-paclitaxel and Cisplatin, nab-paclitaxel，Cisplatin
- Volunteers
- 80 people
- Sponsor
- Yang Jianjun, PhD
Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
- Trial name
- NCT00165490
- Testing
- Cetuximab, Cisplatin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer, Non-small Cell Lung Cancer
Effects of Infusion Timing on Treatment Response in Solid Tumors
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer
- Trial name
- TIMED (NCT07630168)
- Testing
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Neoplasms, Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
This study is conducted to evaluate efficacy and safety of neoadjuvant chemotherapy followed by preoperative chemoradiotherapy in patients with resectable esophageal squamous cell carcinoma
- Conditions
- Esophageal Neoplasms, Squamous Cell Carcinoma, Concurrent Chemoradiotherapy
- Trial name
- NCT03579004
- Testing
- Paclitaxel, Cisplatin, Fluorouracil
- Where
- 2 sites in Russia
- Volunteers
- 48 people
- Sponsor
- Mona Frolova
Esophageal Cancer
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis.
- Trial name
- ECTOP-2005 (NCT05443841)
- Testing
- pleural lavage
- Where
- 11 sites in China
- Volunteers
- 385 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
We plan to conduct a single-center,prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced…
- Trial name
- NCT07312578
- Testing
- Nimotuzumab, camrelizumab, Albumin paclitaxel
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University
Locally Advanced Head and Neck Squamous Cell Carcinoma
Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Over 60% of head and neck squamous cell carcinoma (HNSCC) patients are diagnosed at a locally advanced stage. While standard treatments involve surgery and chemoradiotherapy, prognosis remains poor, with 50-60% experiencing local…
- Trial name
- NCT07371234
- Testing
- Neoadjuvant and Adjuvant Immunotherapy, Low-dose radiotherapy, Surgery
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Rui You
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma
This trial studies the efficacy and safty of paclitaxel in combination with cisplatin and 5-fluorouracil(TPF) induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma.
- Trial name
- NCT02976909
- Testing
- Paclitaxel+Cisplatin+5fluorouracil
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Yuhong Li
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002839
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 20 sites in Belgium, France and 4 more
- Volunteers
- 564 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Neoplasms
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage…
- Trial name
- BelieveIT-201 (NCT05980598)
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Where
- 65 sites in United States, Georgia and 6 more
- Volunteers
- 27 people
- Sponsor
- Ascendis Pharma A/S
Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell…
- Trial name
- NCT07465276
- Testing
- Ficerafusp alfa, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Squamous Cell Carcinoma
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma patients
- Trial name
- NCT05302011
- Testing
- Pembrolizumab, Carboplatin or Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05726370
- Testing
- Pembrolizumab, CISPLATIN, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms, Oral, Mouth Neoplasms
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery.
- Trial name
- NCT01553851
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine